New Treatments & Clinical Trials for Ewing Sarcoma

Ewing sarcoma is a rare bone and soft tissue cancer that mostly affects children and young adults. Standard treatment combines chemotherapy, surgery or radiation, and more chemotherapy. About 70% of people with localized disease are cured, but outcomes for metastatic or relapsed disease remain poor, driving intense research into targeted therapies and immunotherapies.

What's actually going on in research

Trials are testing immunotherapies that train the immune system to recognize Ewing sarcoma cells, targeted drugs that block the IGF-1R pathway the cancer relies on, and combinations that pair chemotherapy with newer agents. Researchers are also studying CAR T-cell therapy, which engineers immune cells to attack the tumor, and drugs that target the EWSR1-FLI1 fusion protein that drives most cases.

What to know before you search

Eligibility typically depends on whether the cancer is newly diagnosed or relapsed, extent of disease, prior treatments received, and overall health to tolerate intensive chemotherapy.

What types of trials are currently open

• Frontline treatment trials — Testing whether adding targeted drugs or immunotherapies to standard chemotherapy improves outcomes for newly diagnosed Ewing sarcoma.
• Relapsed disease trials — Testing new drug combinations, immunotherapies, or CAR T-cells for people whose cancer has returned after initial treatment.
• Targeted therapy trials — Testing drugs that block specific pathways Ewing sarcoma depends on, such as IGF-1R inhibitors or drugs targeting the fusion protein.
• Radiation trials — Studies comparing radiation techniques or testing whether some people can avoid radiation after good response to chemotherapy and surgery.
• Supportive care trials — Testing ways to reduce treatment side effects or improve quality of life during and after intensive chemotherapy.